Orthofix International NV  

(Public, NASDAQ:OFIX)   Watch this stock  
Find more results for ofix
+0.36 (1.13%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.79 - 32.37
52 week 19.35 - 33.43
Open 32.15
Vol / Avg. 142,704.00/328,788.00
Mkt cap 586.72M
P/E     -
Div/yield     -
EPS -0.86
Shares 18.19M
Beta 0.73
Inst. own 91%
Jun 16, 2014
Orthofix International Annual Shareholder Meeting (Estimated) Add to calendar
May 5, 2014
Q1 2014 Orthofix International NV Earnings Release (Estimated) Add to calendar
Mar 27, 2014
Q4 2013 Orthofix International NV Earnings Release
Mar 27, 2014
Q4 2013 Orthofix International NV Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -8.07% -3.72%
Operating margin -6.01% -1.27%
EBITD margin - 9.18%
Return on average assets -8.05% -3.33%
Return on average equity -10.91% -4.40%
Employees 889 -
CDP Score - -


7 Abraham de Veerstraat
+599-9-4658525 (Phone)
+599-9-4616978 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Orthofix International N.V. (Orthofix) is a diversified, global medical device company focused on developing and delivering repair and regenerative solutions to the spine and orthopedic markets. The Company operates in two global business units, which include Spine and Orthopedics. It designs, develops, manufactures, markets and distributes medical equipment used principally by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products and related human cellular and tissue based products (HCT/P products) used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction.

Officers and directors

Ronald A. Matricaria Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Bradley R. Mason President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
David E. Ziegler Interim Chief Financial Officer
Age: 67
Bio & Compensation  - Reuters
Brad Niemann President - BioStim Business
Bio & Compensation  - Reuters
Jeffrey M. Schumm Chief Administrative Officer
Age: 51
Bio & Compensation  - Reuters
Mark Atkinson Chief People Officer
Bio & Compensation  - Reuters
Michael M. Finegan Chief Strategy Officer
Age: 49
Bio & Compensation  - Reuters
Anthony F. Martin PhD., Independent Director
Bio & Compensation  - Reuters
Kathleen T. Regan Independent Director
Bio & Compensation  - Reuters
Maria Degois Sainz Independent Director
Age: 47
Bio & Compensation  - Reuters